U.S. Markets close in 3 hrs 16 mins

Janssen submits NDA to FDA for canagliflozin/metformin

Janssen Research & Development announced it has submitted a New Drug Application to the FDA seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes. Canagliflozin is an investigational, oral medication for the treatment of adult patients with type 2 diabetes. Metformin is a first-line pharmacotherapy that can be used alone or with other medications, including insulin, to treat type 2 diabetes. If approved, this canagliflozin/metformin fixed-dose combination therapy could provide convenience for patients who may benefit from two diabetes medications working in one pill.